Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MannKind Corporation stock logo
MNKD
MannKind
$3.36
-2.0%
$2.93
$2.23
$6.51
$1.06B1.137.98 million shs3.49 million shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$4.40
+2.1%
$4.42
$3.53
$8.59
$407.07M1.732.13 million shs1.98 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.46
+4.3%
$1.20
$0.98
$1.60
$1.06B1.52.49 million shs4.75 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$17.40
+1.6%
$19.73
$8.91
$44.60
$1.08B-0.71508,305 shs415,764 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MannKind Corporation stock logo
MNKD
MannKind
-2.04%-5.35%+18.31%+18.73%-23.98%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+2.09%+11.96%-8.33%-14.23%-9.84%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+4.29%+12.31%+32.73%+24.79%+5.80%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
+1.58%-3.81%-10.12%-31.12%+82.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MannKind Corporation stock logo
MNKD
MannKind
$3.36
-2.0%
$2.93
$2.23
$6.51
$1.06B1.137.98 million shs3.49 million shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$4.40
+2.1%
$4.42
$3.53
$8.59
$407.07M1.732.13 million shs1.98 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.46
+4.3%
$1.20
$0.98
$1.60
$1.06B1.52.49 million shs4.75 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$17.40
+1.6%
$19.73
$8.91
$44.60
$1.08B-0.71508,305 shs415,764 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MannKind Corporation stock logo
MNKD
MannKind
-2.04%-5.35%+18.31%+18.73%-23.98%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+2.09%+11.96%-8.33%-14.23%-9.84%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+4.29%+12.31%+32.73%+24.79%+5.80%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
+1.58%-3.81%-10.12%-31.12%+82.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MannKind Corporation stock logo
MNKD
MannKind
2.60
Moderate Buy$8.97166.93% Upside
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.00
Hold$6.5047.73% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.556.16% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
2.56
Moderate Buy$44.29154.52% Upside

Current Analyst Ratings Breakdown

Latest MYGN, MNKD, ZBIO, and OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Reiterated RatingBuy
6/3/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Reiterated RatingBuy
6/1/2026
MannKind Corporation stock logo
MNKD
MannKind
Set Price TargetOverweight$11.00
5/18/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
DowngradeSell (D-)Sell (E+)
5/18/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
UpgradeSell (E+)Sell (D-)
5/15/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
UpgradeStrong SellHold
5/15/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Reiterated RatingBuy$44.00
5/14/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Boost Price TargetEqual Weight$21.00 ➝ $22.00
5/14/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Reiterated RatingBuy
5/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Boost Price TargetOverweight$8.00 ➝ $10.00
5/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Boost Price TargetBuy$8.00 ➝ $10.00
(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MannKind Corporation stock logo
MNKD
MannKind
$348.97M2.97$0.06 per share55.43($0.17) per share-19.76
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$824.50M0.50$3.86 per share1.14$3.95 per share1.11
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.82N/AN/A$1.67 per share0.87
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$10M109.85N/AN/A$4.51 per share3.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MannKind Corporation stock logo
MNKD
MannKind
$5.86M-$0.07N/A22.40N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$365.90M-$4.30N/AN/AN/A-48.24%-8.51%-4.48%8/4/2026 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$377.74M-$8.47N/AN/AN/AN/A-99.99%-58.06%8/11/2026 (Estimated)

Latest MYGN, MNKD, ZBIO, and OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.4742-$1.46+$0.0142-$1.46$25.00 millionN/A
5/6/2026Q1 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 million
5/5/2026Q1 2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.06-$0.09-$0.03-$0.36$202.42 million$200.40 million
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
4/13/2026Q4 2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A-$1.10N/A-$0.98$40.00 millionN/A
3/16/2026Q4 2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.22-$4.54-$3.32-$4.54$28.75 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MannKind Corporation stock logo
MNKD
MannKind
N/A
1.87
1.50
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.36
2.40
2.19
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.04
11.94
11.94

Institutional Ownership

CompanyInstitutional Ownership
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
MannKind Corporation stock logo
MNKD
MannKind
2.60%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
1.90%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
22.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
MannKind Corporation stock logo
MNKD
MannKind
400308.95 million300.92 millionOptionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70094.45 million92.65 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million379.89 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A63.13 million49.24 millionN/A

Recent News About These Companies

Zenas Biopharma Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

MannKind stock logo

MannKind NASDAQ:MNKD

$3.36 -0.07 (-2.04%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$3.33 -0.03 (-0.98%)
As of 06/3/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$4.40 +0.09 (+2.09%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$4.28 -0.13 (-2.84%)
As of 06/3/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.46 +0.06 (+4.29%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$1.44 -0.02 (-1.44%)
As of 06/3/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$17.40 +0.27 (+1.58%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$17.70 +0.30 (+1.70%)
As of 06/3/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.